Literature DB >> 11579271

Indinavir crystallization around the loop of Henle: experimental evidence.

J P Dieleman1, S Salahuddin, Y S Hsu, D M Burger, I C Gyssens, M C Sturkenboom, B H Stricker, D J Kok.   

Abstract

OBJECTIVE: To determine the probable site of the nephron and the plasma indinavir (IDV) concentration at which intrarenal IDV crystallization occurs.
DESIGN: We performed in vitro crystallization experiments in IDV solutions simulating conditions found in the nephron.
METHODS: To determine intrarenal IDV concentrations at which conditions in the nephron allow crystallization, several concentrations of IDV basic solutions (0-800 mM) were titrated from pH 4.0 to higher pH values until crystals formed within 1 minute. Based on the combination of pH and ionic strength at which crystals formed, we determined the site of the nephron at which this combination was first attained. Based on the capacity for concentration at that site, we were able to measure the corresponding plasma IDV concentration.
RESULTS: Under conditions normally found at the proximal tubule (i.e., pH 6.7 and ionic strength of 200 mM), IDV crystallized at 200 mg/L. Under conditions applying to the loop of Henle, pH 7.4 and ionic strength of 200 mM, IDV crystallized at 125 mg/L, which would correspond to a plasma IDV concentration of 8 mg/L.
CONCLUSIONS: IDV crystallization is most likely in the loop of Henle and may already start at plasma IDV concentrations as low as 8 mg/L. Increasing hydration does not reduce the risk of IDV crystallization in the loop of Henle but instead prevents IDV crystallization and aggregation in the lower urinary tract. It remains to be confirmed whether prevention of high IDV plasma concentrations will reduce the risk of IDV crystallization in the loop of Henle.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579271     DOI: 10.1097/00042560-200109010-00002

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  4 in total

1.  Renal Dysfunction in HIV-1-infected Patients.

Authors:  Jeffrey B. Kopp
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

2.  Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.

Authors:  J-C Wasmuth; I Lambertz; E Voigt; M Vogel; C Hoffmann; D Burger; J K Rockstroh
Journal:  Eur J Clin Pharmacol       Date:  2007-08-10       Impact factor: 2.953

3.  HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.

Authors:  Yenisey Alfonso; Lianet Monzote
Journal:  Open Med Chem J       Date:  2011-03-09

Review 4.  Timelines of the "free-particle" and "fixed-particle" models of stone-formation: theoretical and experimental investigations.

Authors:  D J Kok; W Boellaard; Y Ridwan; V A Levchenko
Journal:  Urolithiasis       Date:  2016-12-03       Impact factor: 3.436

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.